Akebia Therapeutics develops treatments for ischemia and vascular diseases.
Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Its products include prolyl hydroxylase enzyme and phosphatase enzyme. Akebia Therapeutics, Inc. was founded in 2007 and is based in Cincinnati, Ohio.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 4, 2013 | Series C | $41M | 1 | — | — | Detail |
Apr 26, 2011 | Series B | $22M | 1 | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Feb 12, 2020
Arize AI
|
Series Unknown | $4.02M | Artificial Intelligence | — |
Jan 20, 2020
LatchBio
|
Pre-seed | $200K | Artificial Intelligence | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
AgeChem Venture Fund | — | Series C |